Eventide Asset Management, LLC Prometheus Biosciences, Inc. Transaction History

Eventide Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$103.46 - $126.29 $37.5 Million - $45.8 Million	-362,918 Reduced 35.13%	670,020 $71.9 Million
Q4 2022 Feb 13, 2023	SELL	$36.06 - $117.21 $59 Million - $192 Million	-1,636,317 Reduced 61.3%	1,032,938 $114 Million
Q3 2022 Nov 14, 2022	SELL	$28.17 - $59.01 $15.9 Million - $33.2 Million	-563,445 Reduced 17.43%	2,669,255 $158 Million
Q1 2022 May 16, 2022	SELL	$30.13 - $50.0 $15.4 Million - $25.5 Million	-509,807 Reduced 13.62%	3,232,700 $122 Million
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $634,423 - $1.13 Million	28,475 Added 0.77%	3,742,507 $145 Million
Q1 2021 May 14, 2021	BUY	$16.51 - $25.29 $61.3 Million - $93.9 Million	3,714,032 New	3,714,032 $65.6 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.